Previous 10 | Next 10 |
Interpace Biosciences' (NASDAQ: IDXG ) Medicare Administrative Contractor (MAC) announces a new draft local coverage determination (LCD) for the Company’s ThyGeNEXT test, representing an increase of ~$2,400 per assay over previous reimbursement coverage. More news on: Interpa...
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Company’s ThyGeNEXT ® test, representing an incr...
Further Strengthens Business Development Team with Key Hire PARSIPPANY, N.J., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Interpace Bioscience’s subsidiary, Interpace Pharma Solutions today announced that it is continuing to expand a previously announced partnership agreement to jointly...
PARSIPPANY, NJ, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and Pharma Solutions businesses of Interpace are represented together on one easy to n...
Interpace Diagnostics Group, Inc. (IDXG) Q3 2019 Earnings Conference Call November 13, 2019, 04:30 PM ET Company Participants Jack Stover - President and CEO Jim Early - CFO Conference Call Participants Kevin DeGeeter - Oppenheimer and Company Jeffrey Cohen - Ladenburg Thal...
Interpace Diagnostics (NASDAQ: IDXG ): Q3 GAAP EPS of -$0.19 in-line. More news on: Interpace Biosciences, Inc., Earnings news and commentary, Consumer stocks news, , Read more ...
Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date Acquired BioPharma Business in Partnership with Ampersand Diagnostic Test Volume Grew 16% for the Quarter and 22% Year to Date Conference Call and Webcast Wednesday November 13, 2...
PARSIPPANY, NJ, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Company’s financial result...
Clinical Data Highlights the Utility of ThyGeNEXT ® and ThyraMIR ® PARSIPPANY, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Interpace Group (NASDAQ: IDXG) Interpace Diagnostics announced today the publication of two peer-reviewed journal articles and one textbook chapter suppo...
PARSIPPANY, NJ, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89 th Annual Meeting of the American Thyroid Association (ATA), being held October 30 th to November ...
News, Short Squeeze, Breakout and More Instantly...
Interpace Biosciences Inc. Company Name:
IDXG Stock Symbol:
NASDAQ Market:
Interpace Biosciences Inc. Website:
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics ® , a subsidiary of Interpace Biosciences ® (OTCQX: IDXG), is proud to announce that new data demonstrating the application of advanced sequencing technologies in pancreatic cancer was published as an e-ab...
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update. First quarter Net ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...